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ABSTRACT  
Lysosomal storage disorders are currently treated by enzyme replacement therapy 
(ERT) through the direct administration of the unprotected recombinant protein to the 
patients. Herein we present an ionically crosslinked polyelectrolyte complex (PEC) 
composed of trimethyl chitosan (TMC) and α-galactosidase A (GLA), the defective 
enzyme in Fabry disease, with the capability of directly targeting endothelial cells by 
incorporating peptide ligands containing the RGD sequence. We assessed the 
physicochemical properties, cytotoxicity and hemocompatibility of RGD-targeted and 
un-targeted PECs, the uptake by endothelial cells and the intracellular activity of PECs 
in cell culture models of Fabry disease. Moreover, we also explored the effect of 
different freeze-drying procedures in the overall activity of the PECs. Our results 
indicate that the use of integrin-binding RGD moiety within the PEC increases their 
uptake and the efficacy of the GLA enzyme, while the freeze-drying allows keeping 
intact the activity of the therapeutic protein. Overall, these results highlight the potential 
of TMC-based PECs as a highly versatile and feasible drug delivery system for 
improving the ERT of lysosomal storage disorders.  
 
KEYWORDS: Fabry disease, Enzyme Replacement Therapy, Polyelectrolyte 
Complexes, Lysosomal Delivery, α-galactosidase A, Nanomedicine, Trimethyl chitosan 
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1. INTRODUCTION 
Lysosomal storage disorders (LSDs) comprise a group of rare inherited chronic 
diseases characterized by the deficiency of specific enzymes at the lysosomal 
compartment, and the accumulation within these organelles of the macromolecular 
compounds catabolized by those enzymes.
1
 Although individual LSDs have incidences 
of less than 1:100,000, as a group the incidence is calculated to be 1 in 7,700.
2
 
Nowadays, pharmacological treatment is only available for few of the about 50 known 
LSDs.  In most cases such treatment is based on enzyme replacement therapy (ERT), in 
which purified recombinant enzyme is infused into the patient. Generally, the efficacy 
of many ERTs is limited due to the fact that exogenously provided enzymes do not have 
effect on all clinical aspects of the disease, partly due to the irreversibility of some of 
them, but also due to enzyme formulations failure to reach all major target organs in 
therapeutically efficacious doses.
3
 Thus, delivery of therapeutic biomacromolecules to 
specific cellular types and subcellular compartments is a key objective in drug delivery. 
In particular, lysosomal targeting and delivery in various specific tissues has become of 
great interest due to the clinical relevance of enzymes and proteins acting within the 
lysosome.  
Nanoparticle-based drug delivery has been used to improve the activity and delivery 
of therapeutic macromolecules, like proteins and DNA, providing longer blood 
circulation times and protecting sensitive biomacromolecules from protease degradation 
and immune system reactions.
4
 Within the context of protein delivery systems, stimuli-
triggered release is an appealing and promising approach, especially with the use of 
physiological stimuli like the pH drop within endo-lysosomal compartments.
5, 6
 In 
addition, addressing clinically relevant end points by targeted delivery has emerged as 
an approach to maximize the efficiency of a therapeutic macromolecule by strictly 
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localizing its pharmacological activity through controlled biodistribution.
7, 8
 Drug 
delivery to the nucleus or cytoplasm has been extensively explored,
9
 however, 
lysosomal delivery has only lately turned into the focus of attention.
5, 10-17
  
The current ERT therapy relies in the natural cellular transit of lysosomal enzymes. 
As a rule, lysosomal enzymes are produced in the endoplasmic reticulum, glycosylated 
at the Golgi apparatus, where the mannose-6-phosphate (M6P) is added, and then 
secreted to the extracellular space. Thereafter, the enzyme is available for the cells to be 
internalized through M6P receptors and localized in the lysosomes. This is the 
mechanism that allows the ERT
18
 and the reason why enzymes administered by ERT 
have been genetically modified to exhibit an increased glycosylation, allowing better 
interactions through cell-surface receptors that recognize the carbohydrate moieties. 
However, alternative enzyme targeting approaches might be necessary to enhance not 
only the lysosomal destiny of the enzyme but also enzyme accumulation in specific cell 
types.  
α-galactosidase A (GLA) is the lysosomal enzyme responsible for the degradation of 
globotriaosylceramide (Gb3) and other neutral glycosphyngolipids. Its deficiency 
causes the Fabry disease, resulting in the accumulation of Gb3 in the lysosomes of 
various cells and tissues, mainly at the vascular endothelium.
19-21
 Therefore, endothelial 
cells (EC) represent a main target for therapeutical intervention in Fabry disease. Target 
determinants like E-selectin, VCAM-1, ICAM-1 and integrins like αvβ3 and αvβ5 with 
expression restricted to EC and upregulated during inflammation or angiogenesis, may 
help to achieve specific and safe delivery of drugs into EC subsets involved in diseases, 
thereby improving pharmacological efficacy.
22, 23
 Peptide ligands containing the 
arginine-glycine-aspartic acid (RGD) sequence display a strong binding affinity and 
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selectivity to integrins, particularly to integrin αvβ3, and have been conjugated to several 
conventional therapeutic agents for EC targeting and endosomal delivery.
24-27
 
Previously, we have described for the first time the development of a pH-responsive 
nanocarrier for lysosomal delivery of proteins, based on the ionotropic gelation of 
complexes between trimethyl chitosan (TMC) and the lysosomal enzyme GLA, with 
triphosphate ions.
5
 With a good protein loading efficiency (around 65%), these 
polyelectrolyte complexes (PECs) have appropriate physicochemical properties to 
remain stable at physiological temperature and pH (around 7.5), and dissociate and 
release the protein content at endosomal/lysosomal values (pH 4.5 to 5.5). We proved 
that these PECs were efficiently internalized by human cells and mostly accumulated in 
lysosomal compartments, demonstrating their enormous potential as advanced protein 
delivery systems for treatment of lysosomal storage diseases.
5
 
Following these results, in this work we evaluated the intracellular activity of the 
PECs, and the possibility to enhance the efficacy of the TMC-based PECs to deliver 
GLA into the lysosomes of EC by introducing RGD motifs (PEC-RGD). We therefore 
prepared PEC and PEC-RGD and assessed their physicochemical properties, 
cytotoxicity and hemocompatibility, as well as cellular uptake by ECs. We further 
investigated the intracellular activity in primary cultures of mouse aortic endothelial 
cells of GLA deficient mice (MAEC KO cells). In view of optimizing the PEC storage 
conditions, we also explored the freeze-drying process and the effect on the GLA 
activity. 
2. EXPERIMENTAL SECTION 
2.1 Synthesis of N-trimethyl chitosan  
Trimethyl chitosan (TMC) was prepared from chitosan middle-viscous (CS, Fluka) 
with a degree of deacetylation of ∼87%.
5
 via a two-step procedure,
28
 as reported 
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previously.
5
 Briefly, a mixture of 2 g of sieved chitosan, 4.8 g of sodium iodide (NaI), 
11 mL of a 15% aqueous sodium hydroxide (NaOH) solution and 11.5 mL of methyl 
iodide (CH3I) in 80 mL of 1-methyl-2-pyrrolidinone was stirred at 60 °C for 1 h. 
Special care was taken to keep the methyl iodide in the reaction mixture by using a 
Liebig condenser. The product was precipitated using ethanol and thereafter isolated by 
centrifugation. The N-trimethyl chitosan iodide obtained after this first step was washed 
twice with ether on a glass filter to remove the ethanol. It was then dissolved in 80 mL 
of 1-methyl-2-pyrrolidinone and heated to 60ºC, thus removing most of the absorbed 
ether. In a second step, further 4.8 g of NaI, 11 mL of 15% NaOH solution and 7 mL of 
CH3I were added (second addition) with rapid stirring and the mixture was kept at 60 °C 
for 30 min. Additional 2 mL of CH3I and 0.6 g of NaOH pellets were added and the 
stirring was continued for 1 h. The product, precipitated with ethanol as described 
above, was dissolved in 40 mL of a 10% sodium chloride (NaCl) aqueous solution to 
exchange the iodide. The polymer was precipitated with ethanol, isolated by 
centrifugation and thoroughly washed with ethanol and ether. In vacuum drying yielded 
a white, water-soluble product. Finally, it was dissolved in water and freeze-dried 
(freeze dryer ALPHA 1-4 LD, Christ). The product was partially quaternized chitosan 
with ca. 50% of quaternary amines and around 28% degree of primary amines (free 
amines), as determined by 1H NMR. We also observed 22 and 31% of O-methylation 
for C-3 and C-6, respectively.
29
 The molecular weight of the TMC was estimated to be 
202000 g mol
-1
 with a polydispersity of 2.6, via gel permeation chromatography (GPC), 
using Ultrahydrogel 250 and 500 columns and a Waters 24/4 IR detector, in acetate 
buffer 0.5 M, pH 3. Dextran standards were employed for calibration. The product had a 
pKa value of 6.1 and was fully soluble in both water and HEPES buffer at pH 7.4 to 7.5. 
2.2 Fluorescently labeled TMC (TMC-Atto)  
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TMC was conjugated to the fluorescent dye Atto 647N NHS ester (Fluka). Atto 647N 
NHS was first dissolved in dimethyl sulfoxide (DMSO) and then diluted with buffer 
HEPES 10 mM pH 7.4. This solution was added to a TMC solution (in HEPES 10 mM 
pH 7.4) in an approximate molar ratio of 3:1, and left to react for 1 h at room 
temperature under magnetic stirring. Atto 647N-conjugated TMC was separated from 
the free dye using Zeba desalt spin columns (Thermo Scientific). In order to increase the 
amount of conjugated Atto 647N, a second step was performed and the product was 
reacted with freshly prepared Atto 647N NHS solution for another hour and, afterwards, 
separated with Zeba desalt spin columns. The dye-modified TMC (TMC-Atto) solution 
was freeze-dried (freeze dryer VirTis Freezemobile 25L, SP Scientific, UK). The 
amount of dye was estimated to be 0.32 moles dye per mol TMC, via UV-visible 
spectrometry (NanoDrop Spectrophotometer ND-1000, Thermo Scientific). TMC-Atto 
was stored at -20 ºC. 
2.3 RGD-peptide conjugation to TMC (TMC-RGD)  
A RGD cyclic peptide c(RGDfK) derivatized with N-succinimidyl S-acetylthioacetate 
(SATA) through the ε-amine of the lysine was obtained following procedures 
previously described.
11, 30, 31
 Briefly, the linear peptide was synthesized using standard 
SPPS on a 2-chlorotrityl chloride resin. After cleavage with Acetic Acid/TFE/DCM 
(1:1:3), peptide was cyclized by treatment of T3P in EtOAc in presence of TEA and 
DMAP. The final cyclic peptide was deprotected with a mixture of water and TFA 
(1:19) and purified by semiprep RP-HPLC obtaining peptide c(RGDfK) (180.9 mg, 
15%) as a white solid. To a solution of peptide c(RGDfK) (75.9 mg) dissolved in 15 mL 
of borate buffer 0.02 M at pH 8.2 was added 10 equivalents of SATA (290 mg), the 
reaction mixture was stirring during 16 h.
32
 After the completion of the reaction, the 
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crude was evaporated and purified by semiprep RP-HLPC, obtaining the final peptide 
c(RGDfK)-SATA as a solid (13 mg, 14%).  
The obtained peptide was then conjugated to TMC via a N-[γ-
maleimidobutyryloxy]sulfosuccinimide ester crosslinker (sulfo-GMBS, Pierce). First, 
c(RGDfk)-SATA was left overnight at room temperature and under stirring in a solution 
of EDTA 30 mM and NH2OH.HCl 50 mM to eliminate the acetyl protecting group 
yielding c(RGDfk)-sulfhydrylacetamide. In a second step, sulfo-GMBS was added to a 
TMC solution (10 mg mL
-1
 in buffer HEPES 10 mM pH 7.5) in a concentration of 1 
mM and left to react for 60 min under stirring at room temperature. Next, the product 
was separated from the non-reacted crosslinker using Zeba desalt spin columns (Thermo 
Scientific) previously washed 3 times with HEPES buffer solution. This product (TMC-
crosslinker) was then incubated with the cRDGfk-sulfhydrylacetamide for 1 h at room 
temperature and under constant stirring. Finally, the TMC-RGD product was separated 
from the non-reacted c(RGDfk)-sulfhydrylacetamide using Zeba desalt spin columns, 
freeze-dried (freeze dryer ALPHA 1-4 LD, Martin Christ Gefriertrocknungsanlagen 
GmbH) and stored at -20 ºC.  
The bicinchoninic acid (BCA) assay (Micro BCA Protein Assay Kit, Thermo 
Scientific) was used to verify the presence of the RGD peptide in the TMC (TMC-
RGD), and contrasted with the TMC. Solutions of both polymers (TMC and TMC-
RGD, as well as a blank of buffer) were incubated at 37 ºC for 2 h with the BCA assay 
reagents and, afterwards, the absorbance at 562 nm was measured. A calibration curve 
was made by performing the microBCA test on solutions of the free c(RGDfk) at 
concentration from 0 to 6 µg mL
-1
, in parallel to the samples of TMC and TMC-RGD. A 
number of 7 RGD moieties per TMC-RGD molecule was estimated. 
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2.4 Polyelectrolyte complexes formation  
Recombinant GLA was produced in the HEK 293F cell line and purified by affinity 
chromatography. Briefly, the suspension-adapted human embryonic kidney (HEK) cell 
line FreeStyle™ 293-F (Invitrogen™, Life Technologies, ref. R790-07) was used to 
produce GLA by polyethylenimine (PEI)-mediated transient gene expression. Details of 
GLA production and purification have been previously described.
33
 
Polyelectrolyte complexes (PECs) between GLA and TMC were prepared by 
ionotropic gelation with penta-sodium triphosphate (TPP, Fluka).
5
 The PECs were 
obtained by adding TMC solution (solution A) to GLA (+ TPP) solution (solution B) in 
a volume ratio 70:30, followed by vortex mixing for 5 s and 30 min incubation at room 
temperature. For neat PECs, solution A: 35 µg mL
-1
 of TMC, while for fluorescently 
labeled PECs (PEC-Atto), solution A: 35 µg mL
-1
 of TMC:TMC-Atto (70:30 mass 
ratio). Solution B was always 70 µg mL
-1
 GLA and 23 µg mL
-1
 TPP. All solutions were 
in buffer HEPES 10 mM, pH 7.4-7.5. The final GLA concentration of the suspension 
was 21 µg mL
-1
. 
For RGD decorated PECs (PEC-RGD), first, TMC solution (35 µg mL
-1
) was added 
to solution B, and mixed for 5 s. Then, TMC-RGD solution (35 µg mL
-1
) was added to 
the mixture, vortex mixed for 5 s and 30 min incubation at room temperature. The mass 
ratio TMC:TMC-RGD was varied between 100:0 and 50:50, and the final volume ratio 
between TMC solution (TMC+TMC-RGD) and solution B was always 70:30. Mas ratio 
between GLA and TMC was always 0.85 g(GLA)/g(TMC). 
Fluorescently labeled PEC-RGD (PEC-Atto-RGD) were obtained as PEC-RGD but 
replacing TMC solution for (TMC:TMC-Atto solution 70:30 mass ratio). The mass ratio 
between TMC:TMC-Atto:TMC-RGD was 20:30:50. The final volume ratio between 
TMC solution (TMC+TMC-Atto+TMC-RGD) and solution B was 70:30. 
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All PECs were characterized and used as obtained, without further purification or 
separation steps. When necessary, they were stored at 4 ºC. 
2.5 Freeze-drying of PECs 
Prior to freeze drying (FD), the eutectic point of PEC suspensions was determined by 
means of resistivity measurements, using an Autolab PGSTAT 12 potentiostat 
(EcoChemie, NL). In all samples tested, the eutectic point was within the temperature 
range from -23.3 ºC to -24.5 ºC. Therefore, freezing at -40 ºC (the standard freezing 
temperature of the employed freeze-dryer) seemed a reasonable safety limit (without 
relevant loss of sublimation motive strength), even if lower temperatures were also 
tested when freezing in liquid nitrogen. 
FD vials (4 mL) were filled with 1 mL PECs suspension. A LyoMega-30 freeze-dryer 
(Telstar, Terrassa, Spain) equipped with product temperature probes was used. 
Moreover, 40 µL of a 5% mannitol solution in HEPES 10 mM, pH 7.4 were added in 
half of the samples in order to get isoosmotic solutions. The conditions for the different 
freeze-drying cycles tested are detailed in Table 1. All freeze-dried PECs were stored at 
4 ºC, and before characterization 1 mL of ultrapure water was injected inside the vials 
for resuspension. Samples were thereafter identified with the freeze-drying cycle 
employed (FD1, FD2 or FD3), and an M in case mannitol was introduced. 
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Table 1. Freeze-drying protocols used with PECs 
 FD1 FD2 FD3 
Chamber T at product entrance (ºC) 25 -40 -40 
Product T at entrance (ºC) 25 4 -120 
Freezing T (ºC) -40 -40 -40 
Sublimation T (ºC) +20 +20 +20 
Final T (ºC) +30 +30 +30 
Condenser T (ºC) -50 -50 -50 
Vacuum limit (µmHg) 300 300 300 
Total duration (h) 30 24 18 
 
2.6 Dynamic light scattering characterization 
Size and size distribution of PECs was characterized by dynamic light scattering 
(DLS) based on intensity. The instrument (Zetasizer Nano ZS, Malvern Instruments) 
was equipped with a He-Ne laser (λ=633 nm) as the incident beam, and folded capillary 
cells were used. The average size (D), polydispersity index (PDI) and Zeta potential (ξ-
potential) values were determined at 25 ºC. The PDI describes the width of the particle 
size distribution, and scale ranges from 0 (monodisperse) to 1. For a single size 
population following a Gaussian distribution, then the PDI is related to the standard 
deviation (σ) of the distribution in the fashion: PDI=(σ/D)
2
. 
2.7 Cell line cultures 
Human microvascular endothelial cell line CDC/EU.HMEC-1 (HMEC-1) cells were 
provided by Centers for Disease Control and Prevention (CDC-NIDR) and maintained 
in MCDB 131 supplemented with 50 units mL
-1
 penicillin, 50 µg mL
-1
 streptomycin, 10 
mM L-glutamine and 10% fetal bovine serum (FBS). HeLa cells, from human cervix 
carcinoma were obtained from ATTC and maintained in RPMI media supplemented 
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with FBS, antibiotics and L-glutamine. Both cell lines were kept in a 37 ºC humidified 
atmosphere with 5% CO2. Media, sera and antibiotics were purchased from Invitrogen. 
2.8 Cytotoxicity and hemocompatibility of PECs 
Biocompatibility of freshly prepared PECs was evaluated as previously described.
34, 35
 
Briefly, cell cytotoxicity was tested using 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide (MTT) on HeLa and HMEC-1 cells. The former cell line 
was chosen to test the overall toxicity of PECs and the later cell line was included due 
to its endothelial origin and its high expression of αvβ3 integrins. Cells were exposed to 
different doses of PECs (PEC or PEC-RGD) during 72 h, and at the end of the 
incubation period, 5 mg mL
-1
 of MTT solution was added to the wells. Formazan 
crystals were dissolved with DMSO and spectrophotometrically measured at 590 nm 
(Biotek ELx800 Absorbance Microplate Reader, Izasa Scientific). The data are 
expressed as the percentages of viable cells compared to the cell survival of a control 
non-treated group.  
For hemocompatibility tests, mouse red blood cells (RBC) were isolated from three 
wild type C57BL6 mice, resuspended in 2% (v/v) in PBS and exposed to different 
concentrations of freshly prepared PECs during 1 h at 37 ºC.  The amount of 
hemoglobin released was measured in a spectrophotometer at 405 nm (Biotek ELx800) 
and referred to a positive control of 100% hemolysis obtained after incubating RBC 
with 1% of Triton-X. 
2.9 Cell internalization 
To study the integrin mediated internalization of freshly prepared PECs, HMEC-1 
cells were incubated with Atto 647-labeled PECs (12.5 µg mL
-1
) resuspended into 
MCDB 131 without FBS for 10 or 20 min at 37 ºC. Cells were subsequently washed 
twice with Dulbecco’s phosphate buffered saline (DPBS) solution and subjected to 
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fluorescence-activated cell sorting (FACS) analysis. Data acquisition and analysis was 
performed using FACScan (Beckton-Dickinson) and BD FACSDiva software. A 
minimum amount of 10
4 
viable cells were evaluated in each experiment and the 
percentage of positive cells as well as mean fluorescence intensity (MFI) were recorded.  
2.10 Specific enzymatic activity  
GLA enzymatic activity was assayed fluorometrically as described by Desnick et al.
36
 
with the modifications of Mayes et al.
37
 Basically, it was assayed by using 4-
Methylumbelliferyl α-D-galactopyranoside (4-MUG, Sigma Chemical) as substrate, at a 
concentration of 2.46 mM in assay buffer (0.01 M acetic acid, pH 4.5). A typical assay 
reaction mixture contains 100 µL of substrate and 25 µL of the sample. Enzymatic 
reactions took place in agitation (tubes placed in a rotator, set at a rotation speed of 25 
rpm), at 37 ºC for 1 h, and were stopped with 1.25 mL of 0.2 M glycine buffer (pH 
10.4). The released product, 4-methylumbelliferone (4-MU), was determined by 
fluorescence measurement at 365 and 450 nm as excitation and emission wavelengths, 
respectively. Samples of commercial 4-MU (Sigma Chemical) ranging from 5 to 500 ng 
mL
-1
 in 0.2 M glycine buffer pH 10.4, were used to obtain a calibration curve in order to 
transform fluorescence readings into 4-MU concentration. Specific enzymatic activities 
are expressed as “µmol4-MU h
-1
 mgGLA
-1
” (µmol h
-1
 mg
-1
), or as activity concentrations 
(U mL
-1
).  
2.11 NBD-Gb3 assays in endothelial primary cultures of Fabry mice 
Primary cultures of mouse aortic endothelial cells (MAEC) of GLA deficient mice 
(GlatmKul1) were isolated at the ICTS ‘NANBIOSIS’, more specifically the CIBER-
BBN’s In Vivo Experimental Platform at the Functional Validation & Preclinical 
Research (FVPR) area (www.nanbiosis.es/unit/u20-in-vivo-experimental-platform), 
following procedures previously described.
11, 38
 Endothelial origin of isolated cells was 
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confirmed by CD105 staining. For activity assays, cells in passages 2 to 5 were seeded 
in 24 well plates and maintained at 37 ºC and 5% of CO2. 24 h after seeding 8 µM of 
fluorescent N-Dodecanoyl-NBD-ceramide trihexoside (NBD-Gb3, Matreya LCC) was 
added to the cultures along with the specified concentrations of tested compounds (free 
GLA enzyme, freshly prepared PEC, PEC-RGD, freeze-dried PEC), within the range of 
0 to 2.5 µg mL
-1
 of GLA (about 0 to 5 µg mL
-1
 of PECs). After 48 h incubation, cells 
were trypsinized and NBD-Gb3 fluorescent signal was analyzed by flow cytometry 
(FacsCalibur, Beckton Dickinson) and FCS Express v4 software. To calculate the 
percentage of NBD-Gb3 signal, fluorescent signal in control cells (without treatment) 
was established as 100% and the values were normalized accordingly. Viability of PEC-
treated MAEC cells was checked by eye and compared to the non-treated MAEC cells, 
confirming that the integrity of MAEC cells was not affected by the complex 
incubation. Since GLA activity reduces those Gb3 deposits, the percentage of Gb3 loss 
(% Gb3 loss = 100 -% Gb3-NBD signal) was used to plot the results. When needed, 
IC50 values were calculated using GraphPad Prism 5 software.  
2.12 Animal experimentation 
C57Bl6 wild type animals and Gla
tm1Kul
 GLA deficient mice
39
 were used as source of 
red blood cells and MAEC, respectively. Animal care was handled in accordance with 
the Guide for the Care and Use of Laboratory Animals of the Vall d’Hebron University 
Hospital Animal Facility, and following experimental procedures previously approved 
by the Animal Experimentation Ethical Committee at the institution. 
3. RESULTS  
3.1 Preparation and characterization of RGD-conjugated and fluorescently labeled 
PECs 
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The polyelectrolyte complexes (PECs) between GLA and TMC were prepared by 
ionotropic gelation with penta-sodium triphosphate, as previously reported,
5
 and 
characterized by DLS. We obtained particles with diameters in the range of 170 to 215 
nm at room temperature, and ξ-potential values around 19 mV (Table 2). 
To obtain RGD-conjugated-PECs (PEC-RGD), the mass ratio TMC:TMC-RGD was 
varied between 100:0 and 50:50, and the PECs were prepared and characterized by 
DLS. We found that the incorporation of TMC-RGD lead to a slight decrease of PECs 
zeta potential value (19 mV for PEC and 17 mV for PEC-RGD) with no significant 
variation of the average diameter when up to 50% TMC was replaced by TMC-RGD 
(Table 2). In view of the small change observed for the system, we performed additional 
studies with the PEC-RGD obtained using a TMC:TMC-RGD mass ratio of 50:50. 
In a similar manner, TMC was replaced in part by TMC-Atto to obtain fluorescently 
labeled PECs (PEC-Atto), or by TMC-RGD and TMC-Atto, to obtain fluorescently 
labeled RGD-conjugated PECs (PEC-Atto-RGD) (see Experimental section). As shown 
in Table 2, the introduction of the fluorochrome did not significantly alter the PECs 
size. The ξ-potential of both PEC-Atto and PEC-Atto-RGD was around 16 mV, slightly 
lower than that for PEC. PEC labeled Atto 647N have been characterized by single-
molecule fluorescence in a previous report,
5
 revealing that they were homogeneous in 
size and possessed good colloidal stability in water/HEPES and serum free cell culture 
medium.  
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Table 2. DLS average diameter D, PDI and ξ-potential of freshly prepared PEC, PEC-
RGD, PEC-Atto and PEC-Atto-RGD, in 10 mM HEPES buffer pH 7.5, at 25 ºC. 
Depicted results are the average from 3 independent samples.  
Average size  
D  
(Mean ± SD) (nm) 
PDI  
(Mean ± SD)  
ξ-potential 
(Mean ± SD)  
(mV) 
PEC 177 ± 30 0.19 ± 0.08 18.7 ± 3.9 
PEC-RGD 186 ± 11 0.21 ± 0.04 17.0 ± 2.5 
PEC-Atto 241 ± 19 0.12 ± 0.03 16.4 ± 3.4 
PEC-Atto-RGD 212 ± 30 0.13 ± 0.03 16.7 ± 2.9 
 
3.2 Physico-chemical characterization of freeze-dried PEC 
PEC suspensions were freeze-dried following 3 different freezing protocols (see 
Experimental section). PECs were characterized within 24 h after preparation, whereas 
freeze-dried PECs were characterized immediately after resuspension. 
Remarkable differences were observed between different FD cycles (see Table 3). 
Regarding particle size, a notable reduction in the average diameter was observed when 
using FD2 cycle, resulting in a compaction of the particles, and the addition of mannitol 
did not cause any particle size increase. As displayed in the examples of Figure 1, the 
size distribution for PEC-FD2 and PEC-FD2-M was unimodal. Instead, when freeze-
drying following FD1 and FD3 cycles, a slight diameter increase was observed, being 
almost twofold when mannitol was added. On the other hand, higher PDI values were 
obtained for all particles after freeze-drying, even if these were lower than 0.3 for 
PEC-FD1, PEC-FD2 and PEC-FD2-M, which are still acceptable PDI values. Besides, 
minor ξ-potential decrease was observed after freeze-drying by cycles FD1 and FD2, 
whereas an important drop off was achieved after freeze-drying by cycle FD3. 
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However, in general terms, lower ξ-potential values are obtained in formulations 
containing mannitol. Therefore, FD cycle 2 resulted in good preservation of the 
structure after resuspension. 
 
Table 3. DLS average diameter D, PDI and ξ-potential of PEC, PEC-FD1, 
PEC-FD1-M, PEC-FD2, PEC-FD2-M, PEC-FD3 and PEC-FD3-M, in 10 mM HEPES 
buffer pH 7.5, at 25 ºC. Depicted results are the average from 3 different measurements 
of the same sample. 
Average size  
D  
(Mean ± SD)  
(nm) 
PDI 
(Mean ± SD) 
ξ-potential 
(Mean ± SD) 
(mV) 
PEC 267 ± 4 0.15 ± 0.02 18.7 ± 1.1 
PEC-FD1 298 ± 1 0.28 ± 0.01 17.4 ± 3.7 
PEC-FD1-M 574 ± 31 0.64 ± 0.05 16.9 ± 4.1 
PEC-FD2 226 ± 4 0.25 ± 0.03 17.5 ± 1.5 
PEC-FD2-M 226 ± 6 0.28 ± 0.01 17.2 ± 1.8 
PEC-FD3 275 ± 16 0.37 ± 0.07 14.4 ± 2.1 
PEC-FD3-M 464 ± 32 0.44 ± 0.05 11.3 ± 3.4 
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Figure 1. Particle size distribution of freshly prepared PEC, and PEC freeze-dried 
following the protocol 2, with (PEC-FD2-M) and without (PEC-FD2) mannitol. 
3.3 Cytotoxicity and hemocompatibility 
It has been proposed that strong interaction of cationic nanoparticles with the cell 
membrane may cause damage by membrane disruption, leading to cell death.
40
 
Therefore investigation of the potential cytotoxicity of the PECs is important in order to 
exclude biological responses due to cell death. Cell viability of freshly prepared PEC 
and PEC-RGD was evaluated on HeLa (ovarian carcinoma) and on HMEC-1 
(microvasculature endothelial cells) cell lines. HeLa is a reference cell line, routinely 
used in cytotoxicity assays. HMEC-1 is an immortalized human microvascular 
endothelial cell line that retains the morphologic, phenotypic and functional 
characteristics of normal human microvascular endothelial cells.
41
 It was chosen 
because the vascular endothelium represents a target of choice for therapeutic 
intervention in Fabry disease. Cells were exposed during 72 h to different doses of PEC 
or PEC-RGD, up to 5.5 µg mL
-1
, and then evaluated using the MTT assay. For HeLa 
and HMEC-1 cells, cell viability slightly decreased up to values around 80% for the 
highest concentration tested (Figure 2).  
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To test the hemocompatibility of freshly prepared PEC and PEC-RGD, the percentage 
of hemolysis of mouse RBC was assessed for different PEC or PEC-RGD 
concentrations up to 2.7 µg mL
-1
. Hemolysis for both PEC and PEC-RGD was always 
lower than 1% for the tested concentrations (Figure 3). These results indicate that both 
PEC and PEC-RGD cytotoxicity is very low and they do not induce hemolysis in 
concentrations below 5.5 µg mL
-1
. 
 
Figure 2. Effect of freshly prepared PEC and PEC-RGD on HeLa (a) and HMEC-1 (b) 
cell viability. The results presented correspond to the average of 3 independent 
experiments.  
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Figure 3. Effect of freshly prepared PEC and PEC-RGD on the hemolysis of mice 
RBC. The results presented correspond to the average of 3 independent experiments.  
3.4 Cell internalization  
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We have demonstrated in a previous work that the GLA loaded PEC are easily taken 
up by endothelial cells and localized in the lysosomal compartments, when incubated in 
vitro for 2 h.
5
 In the present work, we aimed at comparing the uptake efficiency of PEC 
and PEC-RGD by endothelial cells, as they represent the target of choice for 
therapeutical intervention. HMEC-1 cells were incubated with fluorescently labeled 
PECs, PEC-Atto and PEC-Atto-RGD, for short periods of time, i.e. 10 and 20 min, and 
PECs internalization was evaluated by flow cytometry. As shown in Figure 4a, 15.7 ± 
0.5% and 26.3 ± 2.3% of the cells showed enhanced fluorescence when incubated with 
PEC-Atto for 10 and 20 min, respectively, while incubation with PEC-Atto-RGD for 10 
and 20 min led to 24.4 ± 1.8% and 37.0 ± 1.8% of positive cells, respectively. 
Interestingly, the percentage of positive cells and mean fluorescence intensity (MFI), 
both indicative of the amount of nanoparticles internalized by cells, were higher on 
cultures incubated with the PEC-Atto-RGD as compared to those treated with PEC-
Atto. Such differences were increased for short times (10 min, p = 0.0129, Figure 4), 
indicating that, as expected, receptor mediated internalization through the RGD binding 
of αvβ3 integrins is faster and more efficient than the non-targeted endocytic process. 
 
Figure 4. Uptake of freshly prepared Atto 647N-labeled PEC and PEC-RGD (PEC-Atto 
and PEC-Atto-RGD) in live HMEC-1. a) Flow cytometry quantitation of the fraction of 
cells that had internalized PEC as the percentage of Atto 647N-positive cells among a 
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given number of cells counted and b) mean fluorescence intensity (MFI) of Atto 647N 
in the cells normalized to the maximum fluorescence intensity.  
3.5 Specific enzymatic activity and activity in primary cultures: Gb3 loss in 
endothelial primary cultures of Fabry mice 
Since GLA activity reduces Gb3 deposits within the lysosomes, the efficacy of 
different PECs to diminish the intracellular Gb3 deposits was assessed in cell cultures 
and compared to the activity of free GLA. The percentage of Gb3 loss of primary 
cultures of mouse aortic endothelial cells (MAEC) of GLA deficient mice was evaluated 
after simultaneous incubation with fluorescently labeled Gb3 (NBD-Gb3) and GLA, 
PEC or PEC-RGD in different concentrations. Degradation of NBD-Gb3 by GLA 
occurs exclusively inside the late endosomes/lysosomes, where the pH conditions are 
the most favorable for the enzyme activity. Outside these organelles, the pH is higher, 
and not optimal for the GLA enzymatic activity. Even when GLA and NBD-Gb3 are 
incubated simultaneously with the cells, the reaction only takes place when both 
components are internalized in the lysosomes. 
 Before moving into the cellular activity assays, the specific enzymatic activity of 
free GLA, and freshly prepared PEC and PEC-RGD was first assessed following the 
degradation of 4-MUG fluorometrically, in the conditions described in the Experimental 
section (section 2.10). The specific activity of the GLA is in some extent altered by the 
encapsulation process, as detailed in Table 4. A decrease in activity after encapsulation 
has previously been observed for GLA loaded TMC-based PEC
5
 and it is probably 
related to the more difficult accessibility to the substrate. Dissociation of the PECs and 
accessibility of the enzyme to the substrate is expected to be easier in the lysosome, 
with presence of many degrading enzymes, than in the test tube.  
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Table 4. Specific enzymatic activity of freshly prepared PEC, PEC-RGD and free GLA 
suspension tested in assay tubes (4-MUG degradation assay) 
Protein 
concentration 
(µg mL
-1
) 
Specific enzymatic activity 
(Mean ± SD) 
 (µmol h
-1
 mg
-1
)  (U mL-1) 
GLA 373 1533.5 ± 177.1 9.533 ± 1.101 
PEC 16 487.9 ± 39.8 0.130 ± 0.011 
PEC-RGD 17 406.3± 26.8 0.115 ± 0.008 
 
 Figure 5 displays the Gb3 loss, obtained from the reduction in fluorescence due 
to the degradation of NBD-Gb3, plotted against the concentration of activity of GLA of 
the free GLA, freshly prepared PEC or PEG-RGD suspensions. The GLA concentration 
is represented in activity units (U mL
-1
) due to the variations in specific activity for the 
different samples tested. The curves show higher efficacy for both PEC and PEC-RGD 
when compared to free GLA, as there is a 50% loss of Gb3 (IC50) already at 7.6 ± 0.9 
and 5.5 ± 1.5 mU mL
-1
 activity for PEC and PEC-RGD, respectively, while for the free 
GLA this occurs at an activity of 50.3 ± 8.1 mU mL
-1
. These results suggest that GLA is 
better internalized by MAEC when loaded in the PECs, increasing significantly the 
efficacy (IC50 values for the Gb3 loss is 7.6 ± 0.9 mU mL
-1
 for PEC while naked GLA 
requires 50.3 ± 8.1 mU mL
-1
). In addition, the slight decrease in IC50 for the RGD 
decorated PEC (IC50 values of 5.5 ± 1.5 mU mL
-1
) may be associated with the higher 
internalization degree observed already in HMEC-1 when compared to the bare PECs. 
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Figure 5. In vitro activity of freshly prepared PEC, PEG-RGD and free GLA in primary 
cultures (MAEC KO cells, NBD-Gb3 assays). The mean percentage of Gb3 loss of 
three independent experiments is plotted vs. GLA activity concentration.  
The enzymatic activity of the freeze-dried PEC was tested immediately after 
resuspension in MilliQ water, and compared with the specific activity of the stock PEC 
suspension. Results in Table 5 show that the freeze-drying process not only does not 
affect the enzymatic activity of the encapsulated GLA, but also helps to preserve its 
activity, since all FD-PECs show higher enzymatic activity than the fresh PECs tested 
after 4 days of preparation. This result is very clearly evidenced in the percentage of 
activity recovered displayed in Table 5 with respect to fresh GLA, and with respect to 
fresh PECs of the same batch. When PECs tested 4 days after synthesis retain only 20 % 
of the specific activity of the free fresh GLA, when PECs are FD and resuspended, this 
percentage raises up to almost 50% in the best case. Besides, the presence of mannitol 
in the freeze-drying medium does not have a direct effect on the enzymatic activity in 
the test tube. Finally, although all freeze-dried PECs display good enzymatic activity 
after resuspension, the maximum activity is obtained after the freeze drying cycle 2 
(FD2). 
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Table 5. Specific enzymatic activity of GLA containing freeze-dried PECs and stock 
PEC and GLA suspensions tested in assay tubes (4-MUG degradation assay). All tests 
were performed within the first days after PECs synthesis and immediately after 
resuspension, in the case of freeze-dried PECs. 
Protein 
concentration 
(µg mL-1) 
Specific enzymatic activity 
(Mean ± SD) 
Activity recovered after 
encapsulation/FD 
(%) 
(µmol h-1 mg-1) (U mL-1) 
Respect to 
free fresh 
GLA 
Respect to 
fresh PEC 
GLA 1452 1681 ± 165 40.69 ± 4.00 - - 
PEC 23 333.4 ± 6.7 0.106 ± 0.003 20 - 
PEC-FD1 23 586.2 ± 12.5 0.191 ± 0.005 35 176 
PEC-FD1-M 23 606.2 ±33.5 0.203 ± 0.013 36 182 
PEC-FD2 23 808.3 ± 65.6 0.310 ± 0.025 48 242 
PEC-FD2-M 23 783.0 ± 106 0.300 ± 0.041 47 235 
PEC-FD3 23 549.6 ± 21.6 0.211 ± 0.008 33 165 
PEC-FD3-M 23 582.9 ± 30.0 0.223± 0.012 35 175 
 
 Accordingly, the intracellular activity of the PEC-FD2 was assessed and 
compared with that of the freshly prepared PECs. Figure 6 displays the Gb3 loss plotted 
against the concentration of activity of GLA for PEC, PEC-FD2 and PEC-FD2-M 
suspensions. Both PEC-FD2 and PEC-FD2-M display higher efficacy than PEC, with a 
50% loss of Gb3 (IC50) at 1.5 ± 0.2 and 1.3 ± 0.2 mU mL
-1
 activity for PEC-FD2 and 
PEC-FD2-M, respectively, and at 5.9 ± 0.5 mU mL
-1
 for PEC, probably due to the 
stabilization of the PEC complex after freeze-drying procedure.  
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Figure 6. In vitro activity of freeze-dried PECs in primary cultures (MAEC KO cells, 
NBD-Gb3 assay): Gb3 loss vs. GLA activity after incubation with resuspended PEC-
FD2 and PEC-FD2-M, or freshly prepared PEC. 
4. DISCUSSION 
Pharmacological treatment of LSDs is in most cases based on the ERT with purified 
recombinant enzymes. The lysosomal destiny of infused enzymes by ERT relies in the 
presence of M6P at the protein and its ability to interact with the cell membrane via 
M6P receptors. Enzyme loaded in nanoparticle-based nanocarriers is a promising 
alternative to increase the efficacy of ERT treatment as they can provide a versatile 
platform to tackle several issues dealing with intracellular delivery of therapeutic 
macromolecules. Encapsulation within nanocarries can influence blood circulation 
times and protect biomacromolecules from protease degradation and immune system 
reaction. Furthermore, they allow tailoring the interaction with the cell membrane and 
release of the cargo by tuning the nanoparticle physicochemical properties, 
functionalization with specific ligands, etc, in order to tackle specific tissues, organs, 
cell types, and even organelles.  
Here, we have developed a PEC based on the ionic interaction between the lysosomal 
enzyme GLA, deficient in the LSD called Fabry disease, and TMC, using TPP as ionic 
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crosslinker.
5
 The ionic nature of the PECs has the advantage of simple preparation 
procedures, due to the self-assembling nature of the system, which is of great 
importance when the cargo is a biomacromolecule, sensitive to harsh synthesis 
conditions like high temperatures, solvents or extreme pH.
42
 In addition, it permits 
tailoring of the nanoparticle properties by modifying only one of the PECs components, 
the TMC in this case. Using this strategy, we have developed PECs capable to self-
assemble at neutral pH by simply mixing components and stirring, and disassemble at 
endo-lysosomal acidic pH, where the GLA is active.
43
 The PECs have average D 
between 170 and 250 nm and very low PDI (0.1-0.2) measured by DLS, and positive ξ-
potential in the range of 16-19 mV at pH 7.4 (Table 2), suggesting that the nanoparticles 
surface expose mainly TMC than GLA, as the protein is negatively charged at neutral 
pH.
44
 
It has been proposed that the strong interaction of cationic nanoparticles with the 
negatively charged cell membrane may cause membrane disruption, leading to cell 
death,
40
 but it is also evidence that the toxicity of cationic nanoparticles depends on cell-
specific uptake mechanisms and pathways.
45
 Following safety concerns for future in 
vivo applications, we investigated the potential toxicity of the PECs on HeLa, a 
routinely used cell line for cytotoxicity evaluation, and HMEC-1 cells, as vascular 
endothelial cells represent the main target for therapeutics in Fabry disease.
19-21
 For 
PEC concentrations up to 5.5 µg mL
-1
 cell viability is not significantly affected, 
maintained around 80% (Figure 2). Besides, hemolysis of the PECs suspensions was 
always lower than 1% when tested against mouse RBC (Figure 3), clearly below the 5% 
value considered as the toxicity threshold. These results are in agreement with other 
reports on TMC based nanovectors with low toxicity
46
 and also show a correlation of 
the cytotoxicity with other structural parameters besides surface charge, like size of the 
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nanoparticles, molecular weight of chitosan and acetylation degree.
47
 Moreover, the 
lowered buffering capacity of chitosan after methylation
5
 prevents endo-lysosomal 
disruption and scape,
48
 which in combination with the dissociation capacity of the PECs 
at low pH
5
 and the eventual TMC degradation by lysosomal enzymes,
49
 may preserve 
lysosomal function after PECs internalization. 
In previous studies we demonstrated that the PECs were efficiently internalized by 
HMEC-1 cells in vitro, after 2 h incubation, with endosomal/lysosomal destination 
confirmed by multicolor fluorescence microscopy.
5
 This nonspecific cell uptake most 
likely takes place by adsorptive endocytosis.
50, 51
 Here, we explored the introduction of 
peptides ligands that include the RGD motif in the PECs structure, to target integrins 
like αvβ3, expressed in endothelial cells and upregulated during inflammation or 
angiogenesis and also in Fabry patients.
22-27, 52
 Indeed, the addition of the RGD motif 
has long been seen as a way to enhance the cellular internalization of otherwise slowly 
internalizing nanosystems
26
 and viruses.
53
 In our hands, the same cyclic RGD peptide 
has been introduced previously to nanoliposomes and polyurethane-polyurea 
nanocapsules enhancing the internalization and the lysosomal localization of the 
nanosystem.
11, 30
 Conjugation of c(RGDfk) to TMC is a simple procedure, and allows 
obtaining RGD-conjugated-PECs (PEC-RGD), without significant alterations of the 
particle average diameter and a slight decrease in ξ-potential value (Table 2), probably 
due to the exposure of RGD peptide on the surface. The PEC-RGD showed the same 
cell viability, when evaluated on HeLa and HMEC-1 cell lines (Figure 2), and 
hemocompatibility (Figure 3) of the PECs. Still, versatility of the PECs may allow 
introducing other types of ligands to target for example ICAM-1.
54, 55
 
Using a similar strategy, by conjugation of TMC with a fluorescent moiety (Atto 
647N), fluorescent PEC and PEC-RGD were prepared to follow cell uptake by FACS, 
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also maintaining average D and with a minor decrease in ξ-potential (Table 1). When 
comparing the internalization of PEC and PEC-RGD by HMEC-1 after incubation for 
short times, i.e. 10 and 20 min, an increase in the number of positive cells was observed 
for both PEC and PEC-RGD over time (Figure 4). However, statistically significant 
difference in the amount of positive cells between PEC and PEC-RGD uptake was 
mainly observed at 10 min incubation time. It is important to take into account that, due 
to the preparation method, it is not possible to control the location and orientation of the 
RGD motif within the PEC. The addition of TMC and TMC-RGD solutions to the GLA 
+ TPP solution is done in subsequent steps, in order for the first complexes to be formed 
with the TMC, and then complete the particle formation with the TMC-RGD. We 
expect that the amount of RGD be higher on the outer layers of the PEC than on the 
core; however, we have no evidence to support this hypothesis. Still, even when 
HMEC-1 internalization occurs fast and in great extent for both PEC and PEC-RGD, 
the enhanced uptake of RGD decorated PEC at short incubation times is evidenced 
(Figure 4), suggesting a quick and efficient receptor-mediated uptake, or at least a 
combination of both nonspecific and receptor-mediated endocytosis. 
Preservation of enzymatic activity of GLA after encapsulation in the PECs is 
essential. A first, test following the degradation of 4-MUG fluorometrically revealed 
that GLA in PECs is active, but shows a decrease in activity after encapsulation (Table 
4). This might be related to a hampered accessibility of the substrate because of a partial 
association of the enzyme and TMC persisting at acidic pH. However, it is expected that 
in the lysosomal environment, pH-triggered release will be accompanied by the 
lysosomal enzymes degradation of TMC,
49
 facilitating enzyme-substrate interactions. In 
order to have more representative results of PECs efficacy in vitro, the evaluation of the 
degradation of NBD-Gb3 in primary GLA deficient cultures (Fabry mice) was assessed. 
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As shown, results were promising, as both PEC and PEC-RGD display higher activity 
in MAEC KO cells than free GLA (Figure 5) with significantly lower IC50 (50.3 mU 
mL
-1
 for GLA and 7.6 and 5.5 mU mL
-1
 for PEC and PEC-RGD, respectively). Since 
the GLA requires the low pH at the lysosomes to be active, no metabolization of the 
NBD-Gb3 can occur outside the lysosome by the enzyme.
43
 A first observation is that, 
as already suggested by the cell internalization studies by FACS, both PEC and PEC-
RGD destination is the lysosomes. Notably, an important increase in intracellular 
activity is happening when GLA is encapsulated in PECs respect to the free GLA, even 
when certain loss of specific activity of GLA after encapsulation is happening. 
Consequently, less activity units of GLA are necessary to degrade Gb3 when the 
enzyme is encapsulated. It has been recently reported the increase of GLA activity when 
associated to liposomes,
11
 which has been related to the immobilization of the enzyme 
onto the lipid bilayer. A similar effect may be happening when GLA is interacting with 
TMC after PECs are dissociated inside the endo/lysosomal compartments, and partial 
association with TMC may still take place. Moreover, an increased efficiency due to the 
RGD ligand is detected, probably due to a higher internalization degree, or even to a 
more favorable uptake mechanism. It is well documented that nonspecific cell uptake of 
nanocarriers occurs mainly by endocytic process,
56
 and integrin-mediated 
internalization occurs when the carrier interacts with the cell surface receptors and are 
taken up into the target cells via receptor-mediated endocytosis. In both cases, the 
resulting endocytic vesicles fuse to form early endosomes and then mature into late 
endosomes which ultimately become part of the lysosomes.
22
 The occurrence of the 
uptake via the two different mechanisms is here suggested by the enhanced 
internalization observed in vitro for PEC-RGD than for PEC. This opens the possibility 
of an alternative glycosylation independent targeting
55, 57
 for ERT, and might facilitate 
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the use of non-glycosylated or partially glycosylated enzymes for treatment of LSD via 
ERT. Thus, GLA encapsulation will also endure a protection effect against GLA 
opsonization in the blood stream as previously demonstrated for other systems.
58, 59
 
Increased cellular levels of GLA or its activity in plasma have recently been reported on 
systems where GLA is also stabilized by other means, such as crosslinking and 
PEGylation, giving a prolonged circulatory half-life,
58
 or by the use of chaperones like 
Migalastat HCl.
59
 Moreover, the increased advantage in the intracellular efficacy of the 
GLA when associated to the TMC in the PECs, particularly when decorated with RGD 
targeting moieties, would likely be evidenced when testing them in in vivo Fabry 
murine experimental models. 
Finally, we have demonstrated that the PECs can be freeze-dried (FD) under 
controlled conditions to be preserved and administrated thereafter. We explored several 
FD cycles and the introduction of mannitol (PEC-FD-M), commonly used as a 
cryoprotector but also to achieve isosmotic solutions, to see its effect on the structure 
and properties of PEC-FD. Evaluating the physicochemical properties of the PECs after 
resuspension and the GLA enzymatic activity after the whole cycle allowed determining 
the optimal FD conditions (FD2), i.e. fasting freezing at -40 º C.  Using this cycle, the 
size and ξ-potential of the PECs after resuspension was not altered (Table 3 and Figure 
1) and the specific enzymatic activity of the GLA was preserved (Table 5), for both 
PECs with and without mannitol. The presence of mannitol did not introduce any 
change in physicochemical of the PECs or the biochemical properties of the loaded 
GLA. PEC-FD2 (as well as PEC-FD2-M) showed higher specific enzymatic activity 
than fresh PECs, probably due to the fact that the tests were performed 4 days after 
preparation, and while fresh PECs could lose part of the GLA structure and activity, 
FD-PEC preserved it.
60
 Not only was a higher specific enzymatic activity observed for 
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PEC-FD but also a significant increase in NBD-Gb3 loss when tested on MAEC KO 
cells in vitro, with IC50 values of 5.9 mU mL
-1
 for PEC and 1.5 and 1.3 mU mL
-1
 for 
PEC-FD2 and PEC-FD2-M, respectively (Figure 6). Subsequently, when comparing 
PEC-FD2 with the free GLA in suspension, the increase in efficacy is very high, with 
IC50 values from 50.3 to 1.5 mU mL
-1
. The FD process is a crucial step to preserve the 
PECs stable and active, and it could also serve as a way to slightly concentrate the 
sample when needed. 
5. CONCLUSIONS 
We have developed a versatile protein lysosomal delivery PEC based on the 
negatively charged lysosomal enzyme GLA, deficient in the LSD Fabry disease, and 
TMC, ionically crosslinked with TPP. Given its simple preparation strategy, it allows 
functionalization via conjugation of TMC with different moieties, like fluorophores and 
ligands, and also changing the cargo protein to tackle other LSDs. We evaluated the 
intracellular activity of the GLA loaded PECs, and the possibility of enhancing their 
efficacy as lysosomal delivery vectors in endothelial cells by introducing the RGD 
motif in the nanocarriers (PEC-RGD). We successfully prepared PEC and PEC-RGD 
with good physicochemical properties, low cytotoxicity and good hemocompatibility. 
PECs were efficiently taken up by endothelial cells in vitro, and the internalization was 
significantly higher for PEC-RGD than for PECs at short incubation times. Even more, 
we demonstrated an enhanced efficacy of PEC and PEC-RGD as compared to free GLA 
when evaluating the intracellular activity in primary cultures of GLA deficient mice. 
Relevantly, we optimized a FD protocol that allowed maintaining the physicochemical 
properties of the PECs while improving the biochemical ones, preserving the specific 
enzymatic activity of GLA and enhancing the efficacy in vitro in MAEC KO cells. The 
FD process is essential to preserve the PECs stable and active, and also could serve as a 
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way to concentrate the sample when needed. Overall, the greater in vitro efficacy of 
PECs on primary cultures together with the enhanced specificity via the introduction of 
RGD ligands to enable more of the GLA reaching the endothelial cells, indicate the 
potential of PECs to enhance its efficacy in ERT in vivo and to reduce the amount of 
GLA and the frequency of administration required in current ERT of Fabry patients. 
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